Medacta GroupFRA:6MD +1.42%91 FCF Margin % is -0.09% as of Dec. 2025. GuruFocus rates FRA:6MD with a GF Score™ of 91/100 and a GF Value™ of €178.79 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 815 Medical Devices & Instruments companies, Medacta Group ranks better than 53.87% on this metric.
The historical rank and industry rank for Medacta Group's FCF Margin % or its related term are showing as below:
FRA:6MD'
s FCF Margin % Range Over the Past 10 Years
Min: -2.87 Med: 0.96 Max: 12.79
Current: 1.4
During the past 11 years, the highest FCF Margin % of Medacta Group was 12.79%. The lowest was -2.87%. And the median was 0.96%.
FRA:6MD's FCF Margin % is ranked better than 53.87% of 815
companies
in the Medical Devices & Instruments industry
Industry Median: -0.1
vs FRA:6MD: 1.40
Medacta Group FCF Margin % Related Terms
Medacta Group FCF Margin % Historical Data
* Premium members only.
The historical data trend for Medacta Group's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Medacta Group's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medacta Group FCF Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Medacta Group's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Medacta Group's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medacta Group (FRA:6MD) has a FCF Margin % of -0.09% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Medacta Group and its competitors. According to the industry distribution chart, Medacta Group ranks #376 out of 815 companies in the Medical Devices & Instruments industry, placing it in the top 46.1%.
Is Medacta Group's FCF Margin % too high?
Medacta Group's current FCF Margin % is -0.09%. Based on the distribution chart, Medacta Group ranks #376 out of 815 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Medacta Group has a GF Score™ of 91/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Medacta Group's FCF Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Medacta Group ranks #376 out of 815 companies for FCF Margin %. This puts Medacta Group in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Medical Devices & Instruments company?
A good FCF Margin % depends on the Medical Devices & Instruments industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Medacta Group and its competitors. Medacta Group's current FCF Margin % is -0.09%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medacta Group stock overvalued right now?
Based on GuruFocus' analysis, Medacta Group (FRA:6MD) is currently considered Modestly Undervalued. The stock's GF Value™ is €178.79, compared to a current price of €143.00 — trading 20% below its estimated fair value. The current FCF Margin % is -0.09%. Medacta Group's overall GF Score™ is 91/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Medacta Group (FRA:6MD), the current FCF Margin % is -0.09% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medacta Group (FRA:6MD) Overvalued in 2026?
Based on GuruFocus' analysis, Medacta Group stock appears to be undervalued.
The current stock price of €143.00 is trading 20% below its estimated GF Value™ of €178.79.
GuruFocus considers Medacta Group to be Modestly Undervalued.
Key valuation signals for FRA:6MD:
FCF Margin %: -0.09%
GF Value™: €178.79 vs. price of €143.00 (20% below fair value)
No single metric tells the full story. See the FRA:6MD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medacta Group SA is involved in developing, manufacturing, and distributing orthopedic and neurosurgical medical devices. It specializes in the design, production, and distribution of personalized and sustainable solutions for joint replacement, sports medicine, and spine surgery. Medacta's product portfolio includes hip, knee, shoulder, and spine replacement solutions, along with a comprehensive range of sports medicine. Its products and surgical techniques are supported by an extensive program of surgeon education and engagement initiatives, enabling its offerings to be effective for the patient and surgeon. Geographically, the company derives maximum revenue from EMEA (which includes Europe, Middle East and Africa), followed by North America, Asia-Pacific, and the Latin America markets.
91GF Score
Get the complete analysis for FRA:6MD
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:6MD has been successfully added to your 
